Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2005

01-09-2005

Perlecan Knockdown in Metastatic Prostate Cancer Cells Reduces Heparin-binding Growth Factor Responses in vitro and Tumor Growth in vivo

Authors: Cristiana Savorè, Chu Zhang, Caroline Muir, Riting Liu, Jeffrey Wyrwa, Jun Shu, Haiyen E. Zhau, Leland W.K. Chung, Daniel D. Carson, Mary C. Farach-Carson

Published in: Clinical & Experimental Metastasis | Issue 5/2005

Login to get access
Metadata
Title
Perlecan Knockdown in Metastatic Prostate Cancer Cells Reduces Heparin-binding Growth Factor Responses in vitro and Tumor Growth in vivo
Authors
Cristiana Savorè
Chu Zhang
Caroline Muir
Riting Liu
Jeffrey Wyrwa
Jun Shu
Haiyen E. Zhau
Leland W.K. Chung
Daniel D. Carson
Mary C. Farach-Carson
Publication date
01-09-2005
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2005
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-005-2339-3

Other articles of this Issue 5/2005

Clinical & Experimental Metastasis 5/2005 Go to the issue

OriginalPaper

MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models

OriginalPaper

Enhancement of Nitric Oxide Release in Mouse Inflammatory Macrophages Co-cultivated with Tumor Cells of a Different Origin

OriginalPaper

Genetic and Pathologic Changes associated with Lymphovascular Invasion of Colorectal Adenocarcinoma

OriginalPaper

KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha

OriginalPaper

Modification of an in vivo Lung Metastasis Model of Hepatocellular Carcinoma by Low Dose N-nitrosomorpholine and Diethylnitrosamine

OriginalPaper

A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits